Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

Journal of Clinical Pharmacology

Volumn 54, Issue 10, 2014, Pages 1134-1143

  Majid, Oneeb ^a   Gupta, Anubha ^a   Reyderman, Larisa ^b   Olivo, Martin ^b   Hussein, Ziad ^a  

^a EISAI CO LTD   (Japan)

^b EISAI INC   (United States)

Author keywords

eribulin; metastatic breast cancer; pharmacodynamic; pharmacokinetic; tumor size

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ANTHRACYCLINE; BILIRUBIN; CAPECITABINE; ERIBULIN; TAXANE DERIVATIVE;

ADVANCED CANCER; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOMETRY; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; BREAST CANCER; BREAST METASTASIS; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; LEUKOPENIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TUMOR VOLUME;

EID: 85027953414     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.315     Document Type: Article

References (21)

1. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005; 4 (7): 1086-1095.
2. Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004; 64 (16): 5760-5766.
3. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA,. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008; 7 (7): 2003-2011.
4. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010; 49 (6): 1331-1337.
5. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001; 61 (3): 1013-1021.
6. Eisai, Inc. Halaven prescribing information. 2012. Accessed January 30, 2014. http://www.halaven.com/
7. Kuznetsov G, TenDyke K, Yu MJ, Littlefield BA,. Antiproliferative effects ofhalichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Proc Am Assoc Cancer Res. 2007; 48: 275.
8. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377 (9769): 914-923.
9. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA,. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010; 10 (2): 160-163.
10. Devriese LA, Mergui-Roelvink M, Wanders J, et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs. 2013; 31 (2): 381-389.
11. Devriese LA, Witteveen PO, Marchetti S, et al. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemother Pharmacol. 2012; 70 (6): 823-832.
12. Dubbelman AC, Rosing H, Jansen RS, et al. Mass balance study of [(1)(4)C]eribulin in patients with advanced solid tumors. Drug Metab Dispos. 2012; 40 (2): 313-321.
13. Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 2009; 15 (12): 4207-4212.
14. Lesimple T, Edeline J, Carrothers TJ, et al. A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. Invest New Drugs. 2013; 31 (4): 900-909.
15. Mukohara T, Nagai S, Mukai H, Namiki M, Minami H,. Eribulin mesylate in patients with refractory cancers: a Phase I study. Invest New Drugs. 2012; 30 (5): 1926-1933.
16. Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res. 2009; 15 (12): 4213-4219.
17. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010; 28 (25): 3922-3928.
18. Kaufman PA, Awada A, Twelves C, Phase A, III, et al. Open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res. 2012; 72 (24 Suppl 3):.Abstract nr S6-6.
19. Lu JF, Claret L, Sutjandra L, et al. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemother Pharmacol. 2010; 66 (6): 1151-1158.
20. Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther. 2009; 86 (2): 167-174.
21. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13 (2): 143-151.